These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29319843)

  • 101. Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis.
    Mitchell B; Kormelink L; Kuhn R; Schadler A; Autry E
    Pediatr Pulmonol; 2023 Jan; 58(1):239-245. PubMed ID: 36203329
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
    Chang D; Liem L; Malogolowkin M
    Pediatr Infect Dis J; 1994 Nov; 13(11):969-74. PubMed ID: 7845750
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Impact of the Implementation of a Vancomycin Protocol on Trough Serum Vancomycin Concentrations in a Pediatric Intensive Care Unit.
    Rezende RQ; Dias CAG; Ricachinevsky CP; de Lucena Capelari JP
    Paediatr Drugs; 2021 May; 23(3):299-305. PubMed ID: 33830468
    [TBL] [Abstract][Full Text] [Related]  

  • 104. An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients.
    Huang X; Yu Z; Bu S; Lin Z; Hao X; He W; Yu P; Wang Z; Gao F; Zhang J; Chen J
    Drug Des Devel Ther; 2021; 15():1549-1559. PubMed ID: 33883878
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Achieving therapeutic vancomycin levels in pediatric patients.
    Hoang J; Dersch-Mills D; Bresee L; Kraft T; Vanderkooi OG
    Can J Hosp Pharm; 2014 Nov; 67(6):416-22. PubMed ID: 25548398
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.
    McDade EJ; Hewlett JL; Moonnumakal SP; Baker CJ
    J Pediatr Pharmacol Ther; 2016; 21(2):155-61. PubMed ID: 27199623
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Failure of prediction of peak serum vancomycin concentrations from trough values in neonates.
    Fofah OO; Karmen A; Piscitelli J; Brion LP
    Pediatr Infect Dis J; 1999 Mar; 18(3):299-301. PubMed ID: 10093959
    [No Abstract]   [Full Text] [Related]  

  • 108. Prediction of vancomycin dose on high-dimensional data using machine learning techniques.
    Huang X; Yu Z; Wei X; Shi J; Wang Y; Wang Z; Chen J; Bu S; Li L; Gao F; Zhang J; Xu A
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):761-771. PubMed ID: 33835879
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections].
    Reis AG; Grisi SJ
    J Pediatr (Rio J); 1996; 72(4):225-9. PubMed ID: 14688932
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Defining Target Vancomycin Trough Concentrations for Treating Staphylococcus aureus Infection in Infants Aged 0 to 90 Days.
    Gwee A; Cranswick N; McMullan B; Bolisetty S; Hunt RW; Curtis N; Duffull SB
    JAMA Pediatr; 2019 Aug; 173(8):791-793. PubMed ID: 31180478
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Vancomycin trough level and loading dose.
    Tuon FF; Romero R; Gasparetto J; Cieslinski J
    Infect Drug Resist; 2018; 11():2393-2396. PubMed ID: 30538506
    [No Abstract]   [Full Text] [Related]  

  • 112. Incorrect Vancomycin Trough Concentrations in Results.
    JAMA Pediatr; 2019 Aug; 173(8):801. PubMed ID: 31381080
    [No Abstract]   [Full Text] [Related]  

  • 113. Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis: Is It Time to Move Past Trough Concentrations?
    Fusco NM; Prescott WA; Meaney CJ
    Pediatr Infect Dis J; 2019 Mar; 38(3):258-262. PubMed ID: 29742643
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.
    Magréault S; Roy C; Launay M; Sermet-Gaudelus I; Jullien V
    Clin Pharmacokinet; 2021 Apr; 60(4):409-445. PubMed ID: 33486720
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Prediction of Vancomycin Dose for Recommended Trough Concentrations in Pediatric Patients With Cystic Fibrosis.
    Amin RW; Guttmann RP; Harris QR; Thomas JW
    J Clin Pharmacol; 2018 May; 58(5):662-665. PubMed ID: 29319843
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
    Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
    Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
    Fung L
    Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
    Tkachuk S; Collins K; Ensom MHH
    Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis.
    Steinmetz T; Eliakim-Raz N; Goldberg E; Leibovici L; Yahav D
    Clin Microbiol Infect; 2015 Jul; 21(7):665-73. PubMed ID: 25887712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.